MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union levelAccess, NewsOctober 29, 2024
EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsAccess, MyelomaMay 28, 2025
A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, Myeloma, NewsJuly 17, 2024
The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, MyelomaJuly 9, 2024
EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patientsAccess, Myeloma, NewsNovember 20, 2024
EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myelomaAccess, MyelomaJune 27, 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, MyelomaApril 29, 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, NewsMarch 3, 2025
